Company intelligence / Profile preview
Script Biosciences
Philadelphia, Pennsylvania, United Statesscriptbiosciences.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Script Biosciences is developing a proprietary CRISPR-based genome editing technology called CasPlus, paired with advanced lipid nanoparticle delivery systems. Their lead preclinical program targets the mismatch repair gene MSH3 to halt progression of triplet repeat expansion diseases such as Huntington's disease and myotonic dystrophy type I. The company claims superior precision and efficiency compared to existing technologies but has not yet reported clinical results[1][2].
- Therapeutic areas
- Neurology
- Modalities
- Gene editing (CRISPR-based)mRNA/LNP delivery systems
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
New York University – exclusive worldwide license for CasPlus technology[2]
Beyond the preview
Go deeper on Script Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Script Biosciences.